Use of histones for therapeutic purposes

Abstract

The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.

1 . The use of at least one human recombinant histone, especially at least one histone of the H1 subtype, and/or a therapeutically effective histone segment as basis for the therapeutic treatment of thrombocytopenia. 
     
     
         2 . A histone and/or its therapeutically effective segment as set forth in  claim 1  for the therapeutic treatment of thrombocytopenia as concomitant manifestation of hematological disorders. 
     
     
         3 . A histone and/or its therapeutically effective segment as set forth in  claim 1  for the therapeutic treatment of thrombocytopenia during or after a therapy for the treatment of hematological disorders, especially after chemotherapy. 
     
     
         4 . A histone and/or its therapeutically effective segment as set forth in  claim 1  for the therapeutic treatment of leukemia, especially acute myeloid leukemia with simultaneous therapeutic treatment of thrombocytopenia. 
     
     
         5 . A histone and/or its therapeutically effective segment as set forth in  claim 1  for therapy in the case of a thrombocytopenia resulting from a disorder of any etiology. 
     
     
         6 . A histone and/or its therapeutically effective segment as set forth in  claim 5  for prohylactic therapy in the case of a threatening thrombocytopenia resulting from a disorder of any etiology. 
     
     
         7 . A histone and/or its therapeutically effective segment as set forth in  claim 1 , characterized in that it is recombinant human histone H1.3.